• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Leukemias - Pipeline Review, Q3 2011 - Product Image

Leukemias - Pipeline Review, Q3 2011

  • ID: 1863314
  • July 2011
  • 748 pages
  • Global Markets Direct

Leukemias - Pipeline Review, Q3 2011

Summary

Global Markets Direct’s, 'Leukemia - Pipeline Review, Q3 2011', provides an overview of the Leukemia therapeutic pipeline. This report provides information on the therapeutic development for Leukemia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Leukemia. 'Leukemia - Pipeline Review, Q3 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Leukemia.
- A review of the Leukemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- READ MORE >

Note: Product cover images may vary from those shown



List of Tables
List of Figures
Introduction
Leukemias Overview
Therapeutics Development
Leukemias Therapeutics under Development by Companies
Leukemias Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Mid Clinical Stage Products
Early Clinical Stage Products
Discovery and Pre-Clinical Stage Products
Leukemias Therapeutics - Products under Development by Companies
Leukemias Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Leukemias Therapeutics Development
Leukemias - Therapeutics Assessment
Late Stage Drug Profiles
Leukemias Therapeutics – Drug Profile Updates
Leukemias Therapeutics - Discontinued Products
Appendix
Methodology
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Leukemias, Q3 2011
Products under Development for Leukemias – Comparative Analysis, Q3 2011
Number of Products under Development by Companies, Q3 2011
Number of Products under Development by Companies, Q3 2011
Number of Products under Development by Companies, Q3 2011
Number of Products under Development by Companies, Q3 2011
Number of Products under Development by Companies, Q3 2011
Number of Products under Development by Companies, Q3 2011
Number of Products under Development by Companies, Q3 2011
Number of Products under Investigation by Universities/Institutes, Q3 2011
Number of Products under Investigation by Universities/Institutes, Q3 2011
Number of Products under Investigation by Universities/Institutes, Q3 2011
Number of Products under Investigation by Universities/Institutes, Q3 2011
Number of Products under Investigation by Universities/Institutes, Q3 2011
Number of Products under Investigation by Universities/Institutes, Q3 2011
Number of Products under Investigation by Universities/Institutes, Q3 2011
Number of Products under Investigation by Universities/Institutes, Q3 2011
Number of Products under Investigation by Universities/Institutes, Q3 2011
Number of Products under Investigation by Universities/Institutes, Q3 2011
Number of Products under Investigation by Universities/Institutes, Q3 2011
Number of Products under Investigation by Universities/Institutes, Q3 2011
Number of Products under Investigation by Universities/Institutes, Q3 2011
Number of Products under Investigation by Universities/Institutes, Q3 2011
Number of Products under Investigation by Universities/Institutes, Q3 2011
Number of Products under Investigation by Universities/Institutes, Q3 2011
Number of Products under Investigation by Universities/Institutes, Q3 2011
Number of Products under Investigation by Universities/Institutes, Q3 2011
Number of Products under Investigation by Universities/Institutes, Q3 2011
Number of Products under Investigation by Universities/Institutes, Q3 2011
Comparative Analysis by Late Stage Development, Q3 2011
Comparative Analysis by Mid Clinical Stage Development, Q3 2011
Comparative Analysis by Early Clinical Stage Development, Q3 2011
Comparative Analysis by Discovery and Pre-Clinical Stage Development, Q3 2011
Products under Development by Companies, Q3 2011
Products under Development by Companies, Q3 2011
Products under Development by Companies, Q3 2011
Products under Development by Companies, Q3 2011
Products under Development by Companies, Q3 2011
Products under Development by Companies, Q3 2011
Products under Development by Companies, Q3 2011
Products under Development by Companies, Q3 2011
Products under Development by Companies, Q3 2011
Products under Development by Companies, Q3 2011
Products under Development by Companies, Q3 2011
Products under Development by Companies, Q3 2011
Products under Development by Companies, Q3 2011
Products under Development by Companies, Q3 2011
Products under Development by Companies, Q3 2011
Products under Development by Companies, Q3 2011
Products under Development by Companies, Q3 2011
Products under Development by Companies, Q3 2011
Products under Development by Companies, Q3 2011
Products under Development by Companies, Q3 2011
Products under Development by Companies, Q3 2011
Products under Development by Companies, Q3 2011
Products under Development by Companies, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Bristol-Myers Squibb Company, 2011
Genzyme Corporation, 2011
Johnson & Johnson, 2011
Boehringer Ingelheim GmbH, 2011
F. Hoffmann-La Roche Ltd., 2011
Kyowa Hakko Kirin Co., Ltd., 2011
Abbott Laboratories, 2011
Biogen Idec Inc., 2011
Amgen Inc., 2011
Sanofi-Aventis, 2011
AstraZeneca PLC, 2011
Eli Lilly and Company, 2011
Athersys, Inc., 2011
GlaxoSmithKline plc, 2011
Genentech, Inc., 2011
MedImmune LLC, 2011
Gilead Sciences, Inc., 2011
Daiichi Sankyo Company, Ltd, 2011
medac GmbH, 2011
Merck & Co., Inc., 2011
AbGenomics International, Inc., 2011
Emergent BioSolutions Inc., 2011
Lentigen Corporation, 2011
Micromet, Inc., 2011
Gamida Cell Ltd., 2011
Generex Biotechnology Corporation, 2011
Takeda Pharmaceutical Company Limited, 2011
ExonHit Therapeutics SA, 2011
Nanotherapeutics, Inc., 2011
Bio-Path Holdings, Inc., 2011
BioSante Pharmaceuticals, Inc., 2011
Aldagen, Inc., 2011
The University of Texas M. D. Anderson Cancer Center, 2011
ZIOPHARM Oncology, Inc., 2011
Novartis AG, 2011
BioMarin Pharmaceutical Inc., 2011
Cephalon, Inc., 2011
Eisai Co., Ltd., 2011
Genta Incorporated, 2011
Hanmi Pharmaceutical Co Ltd, 2011
ImmunoGen, Inc., 2011
Nippon Shinyaku Co., Ltd., 2011
Pfizer Inc., 2011
Sunesis Pharmaceuticals, Inc., 2011
SuperGen, Inc., 2011
Genmab A/S, 2011
Enzon Pharmaceuticals, Inc., 2011
Santaris Pharma A/S, 2011
Astex Therapeutics Limited, 2011
Cyclacel Pharmaceuticals Inc., 2011
Celgene Corporation, 2011
Bayer AG, 2011
Incyte Corporation, 2011
Geron Corporation, 2011
Duke University, 2011
Merck KGaA, 2011
Access Pharmaceuticals, Inc., 2011
4SC AG, 2011
EntreMed, Inc., 2011
EpiCept Corporation, 2011
Hana Biosciences, Inc., 2011
AEterna Zentaris Inc., 2011
IMMUNOMEDICS, INC, 2011
InNexus Biotechnology Inc., 2011
Ligand Pharmaceuticals Incorporated, 2011
Ariad Pharmaceuticals, Inc., 2011
Lorus Therapeutics Inc, 2011
Avalon Pharmaceuticals, Inc., 2011
MethylGene Inc, 2011
Callisto Pharmaceuticals, Inc., 2011
Cleveland BioLabs, Inc., 2011
OncoVista Innovative Therapies, Inc., 2011
OXiGENE, Inc., 2011
Critical Outcome Technologies Inc., 2011
Alexion Pharmaceuticals, Inc., 2011
BioCryst Pharmaceuticals, Inc., 2011
Portola Pharmaceuticals, Inc., 2011
CSL Limited, 2011
Telik, Inc., 2011
TopoTarget A/S, 2011
Dana-Farber Cancer Institute, 2011
CytRx Corporation, 2011
Pharmacyclics, Inc., 2011
Array BioPharma Inc., 2011
MorphoSys AG, 2011
Threshold Pharmaceuticals, Inc., 2011
Synta Pharmaceuticals Corp., 2011
CrystalGenomics, Inc., 2011
Natco Pharma Limited, 2011
Sareum Holdings plc, 2011
Clavis Pharma ASA, 2011
Innate Pharma SA, 2011
Simcere Pharmaceutical Group, 2011
Piramal Life Sciences Limited, 2011
SymBio Pharmaceuticals Limited, 2011
Cellerant Therapeutics, Inc., 2011
Baylor College of Medicine, 2011
InDex Pharmaceuticals AB, 2011
Debiopharm Group, 2011
Chroma Therapeutics Ltd., 2011
Avaris, 2011
Ambit Biosciences Corporation, 2011
Immupharma Plc, 2011
Memgen, LLC., 2011
Actinium Pharmaceuticals, Inc., 2011
Abiogen Pharma S.p.A., 2011
Multimmune GmbH, 2011
BioMAS Ltd., 2011
ERYtech Pharma, 2011
ViroStatics, srl, 2011
Curacyte AG, 2011
MAT Biopharma, 2011
Aquinox Pharmaceuticals Inc., 2011
Celator Pharmaceuticals, Inc., 2011
Altor BioScience Corporation, 2011
Ascenta Therapeutics, Inc., 2011
TMRC Co., Ltd., 2011
Coronado Biosciences, Inc., 2011
Pharmascience Inc., 2011
Eleos Inc., 2011
Arno Therapeutics, Inc., 2011
Fresenius Biotech GmbH, 2011
Syntrix Biosystems, Inc., 2011
Semafore Pharmaceuticals, Inc., 2011
S-BIO Pte Ltd, 2011
Deciphera Pharmaceuticals, LLC, 2011
Xigen SA, 2011
Affichem, 2011
Stemline Therapeutics, Inc., 2011
Synageva BioPharma Corp., 2011
Avila Therapeutics, Inc., 2011
Proacta, Inc., 2011
Polyphenon Pharma, 2011
Onconova Therapeutics, Inc, 2011
MolMed S.p.A., 2011
Syndax Pharmaceuticals, Inc., 2011
Myriad Pharmaceuticals, Inc., 2011
OncoMune, LLC, 2011
Morphogenesis, Inc., 2011
Juvaris BioTherapeutics, Inc., 2011
Esperance Pharmaceuticals, Inc., 2011
Trillium Therapeutics Inc., 2011
Cancer Vaccines Limited, 2011
Globeimmune, Inc., 2011
SBI Biotech Co., Ltd., 2011
Tragara Pharmaceuticals, Inc., 2011
PharmaMar, S.A., 2011
Bellicum Pharmaceuticals, Inc., 2011
KaloBios Pharmaceuticals, Inc., 2011
Aprea AB., 2011
Kinex Pharmaceuticals, LLC, 2011
Cylene Pharmaceuticals, Inc., 2011
SymbioTec GmbH, 2011
GlycoMimetics, Inc., 2011
Lipopharma, 2011
Biothera, 2011
Nereus Pharmaceuticals, Inc., 2011
Advanced Cancer Therapeutics, 2011
The Alize Pharma Group, 2011
Kanisa Pharmaceuticals, Inc., 2011
LFB Biotechnologies, S.A.S.U., 2011
Interprotein Corporation, 2011
Targa Therapeutics Corp., 2011
British Canadian Biosciences Corp., 2011
Sentinel Oncology Limited, 2011
Polaris Group, 2011
ImQuest Life Sciences, 2011
The Vaccine Company L.P., 2011
Immunovative Therapies, Ltd., 2011
Advancell, 2011
Assessment by Monotherapy Products, Q3 2011
Assessment by Combination Products
Assessment by Stage and Route of Administration, Q3 2011
Assessment by Molecule Type, Q3 2011
Leukemias Therapeutics – Drug Profile Updates
Discontinued Products

List of Figures
Number of Products under Development for Leukemias, Q3 2011
Products under Development for Leukemias – Comparative Analysis, Q3 2011
Products under Development by Companies, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Late Stage Products, Q3 2011
Mid Clinical Stage Products, Q3 2011
Early Clinical Stage Products, Q3 2011
Discovery and Pre-Clinical Stage Products, Q3 2011
Assessment by Monotherapy Products, Q3 2011
Assessment by Combination Products, Q3 2011
Assessment by Route of Administration, Q3 2011
Assessment by Stage and Route of Administration, Q3 2011
Assessment by Molecule Type, Q3 2011
Assessment by Stage and Molecule Type, Q3 2011

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos